Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104942 | 0.94 | CYP2A6 (0.54) | CYP2A6CYP1A2ALDH1A1TDP1ITK | |
| SCHEMBL806471 | 0.93 | CYP2A6 (0.59) | CYP2A6CYP1A2ALDH1A1TDP1ITK | |
| SCHEMBL18852193 | 0.88 | CYP2A6 (0.52) | CYP2A6CYP1A2ALDH1A1TDP1ITK | |
| SCHEMBL1341822 | 0.86 | CYP2A6 (0.52) | CYP2A6ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29489123 | 0.86 | CYP2A6 (0.52) | CYP2A6ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL811007 | 0.80 | CYP11B1 (0.51) | CYP2A6ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13074509 | 0.79 | CYP2A6 (0.50) | CYP2A6ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL811121 | 0.78 | CYP11B1 (0.50) | CYP2A6ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1344485 | 0.78 | CYP2A6 (0.54) | CYP2A6ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29489119 | 0.78 | CYP2A6 (0.54) | CYP2A6ALDH1A1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8268990-A | — | — | None | — | — | JP | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021135725-A1 | ORGANIC COMPOUND, ELECTRONIC DEVICE AND ELECTRONIC APPARATUS USING SAME | 陕西莱特光电材料股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200048230-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT INCLUDING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
| US-20190292169-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| EP-0936215-A1 | PROCESS FOR PREPARING 2-PHENYL-3-NAPHTHYLPROPIONIC ACID DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| US-5866577-A | AN ANTICOAGULANT AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-02 | — | — | US | disclosed |
| CN-1168886-A | Process for production of amidinobenzofuran and amidionbenzothiophen derivatives and salt thereof | DAIICHI SEIYAKU CO (JP) | 1997-12-31 | — | — | CN | disclosed |
| CN-1168885-A | Process for prodn. of amidinoindole derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1997-12-31 | — | — | CN | disclosed |
| US-5620991-A | ANTICOAGULANTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| US-5576343-A | ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| JP-H08268990-A | PRODUCTION OF 7-METHYL-2-NAPHTHALENECARBONITRILE | DAI ICHI SEIYAKU CO LTD | 1996-10-15 | — | — | JP | disclosed |
| EP-0540051-B1 | Aromatic amidine derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1996-04-03 | — | — | EP | disclosed |
| CN-1072677-A | Aromatic amidine derivative and salt thereof | DAIICHI SEIYAKU CO (JP) | 1993-06-02 | — | — | CN | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | CYP2A6 1430/4885CYP1A2 572/4885ALDH1A1 1739/4885 |
| US-20200048230-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT INCLUDING SAME | CRY1, CRY2, CYP1A1 | CYP2A6 151/4885CYP1A2 15/4885ALDH1A1 18/4885 |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | CYP2A6 1601/4885CYP1A2 1023/4885ALDH1A1 2931/4885 |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | CYP2A6 818/4885CYP1A2 500/4885ALDH1A1 319/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | CYP2A6 818/4885CYP1A2 500/4885ALDH1A1 319/4885 |
| US-20190292169-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | LAGE3, PPOX, SUN2 | CYP2A6 1105/4885CYP1A2 38/4885ALDH1A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.